Diagnosis and Work-Up of 72 Consecutive Patients with Neuroendocrine Neoplasms at a Swiss Tertiary Referral Center Abstract #656

Introduction: Neuroendocrine neoplasms (NENs) are rare and heterogeneous tumors.
Aim(s): To better characterize the NEN patients followed in two referral centers, and to evaluate the diagnostic and therapeutic procedures adopted.
Materials and methods: Data were obtained from SwissNET, a nation-wide prospective database. Seventy-two consecutive patients (36 men, 36 women) presenting between January 2008 and November 2012 are included in the analysis.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Pathology, grading, staging
Presenting Author: Prof Francois Pralong
Keywords: NEN, cohort

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid
Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Eleni Armeni
#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)
Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#2991 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasia G3 (NEN G3) According to 2019 WHO Classification: A Comprehensive Clinicopathological Characterization Including Mismatch Repair (MMR) Proteins, PDL1 Expression and KRAS/BRAF Status
Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD Gonzalo Ruiz
Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS
#1912 Skeletal-Related Events (SREs) and Use of Antiresorptive Therapy (ART) in Patients with Bone Metastases of Neuroendocrine Neoplasms
Introduction: Antiresorptive therapy (ART) with bisphosphonates or denosumab is effective in preventing skeletal-related events (SREs) in patients with bone metastases (BM). In neuroendocrine neoplasms (NEN), BM are a negative prognostic factor, however tend to be asymptomatic and SREs are considered rare. The role of ART in preventing SREs in NEN has not been investigated so far.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Others
Presenting Author: Dr. med. Leonidas Apostolidis
#1931 Quality of Life, Anxiety and Depression in Patients with NEN after Surgery
Introduction: Less is known about quality of life and psychiatric disorders in surgical cohort of NEN patients (pts.).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. Nehara Begum